According to the in-depth study published by MarkNtel Advisors, the Global GLP-1 Receptor Agonist Market is projected to grow at a CAGR ...

I’ve been hearing a lot lately about how it’s “taking the easy way out” to use GLP-1s to lose weight. That stands for ...

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term safety, side effects, and global accessibility. Researchers stress ...

Patients with T2DM and autoimmune thyroiditis using semaglutide show lower rates of surgery and radiation for thyroid eye disease at 5 years.

The 57-year-old star - who recently recalled Donald Trump's insistence to have her join The Apprentice cast - called her ...

All-cause mortality significantly lower with GLP-1 RA use, with consistent benefit across major cancer types, most GLP-1 RA types.

A slow NHS rollout has so far limited wide-ranging eligibility, meaning many patients have turned to private healthcare.

Glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes or weight management is associated with a lower risk of developing colon cancer.

Margaret Cho, 57, says that GLP-1 medications have been a "lifesaver" in managing the "self-soothing" cravings from her binge ...

This randomized clinical trial found that continuing glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide ...